Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients

Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT

In this clinical study the Notal Vision Home OCT (NVHO) Monitoring System will be used to evaluate the ability of patients diagnosed with DME to perform sequential self-images of their eyes with the self-operated NVHO device in a home simulated environment in the doctor's office.

The study population will include up to 30 patients, with DR in at least one eye at the time of enrollment. All subjects will be enrolled at one site in Israel.

Study Overview

• Status: Completed
• Conditions: Diabetic Retinopathy

Detailed Description

Office Visit NOTE: Any planned treatment for DME at the day of the study should be administered after completion of all study-related scans

At the enrollment Office Visit, the exams will be conducted in the following order:

1. Patient will be informed concerning the study and sign the Informed Consent Form (ICF) prior to conduct of any study procedures.
2. Following signing the ICF, subjects will be assigned a Subject ID by a designated staff at the clinical site.

3. The following data will be collected for each study subject:

   1. Date of birth
   2. Gender
   3. Number and type of Anti-VEGF injections and last injection date

3. Refraction correction 4. Snellen BCVA on both eyes on the day of the visit. 5. Eligible eye(s) of the subject will be scanned, non-dilated, with a Zeiss Cirrus OCT device with one (1) acceptable volume scan of each eye being obtained out of up to 3 attempts.

Scanning pattern to be used:

Macular cube, 6X6mm, 128 B-scans per volume scan 6. Eyes of the subject that meet all screening criteria will be enrolled. If both eyes of the subjects meet all screening criteria both eyes will be enrolled.

NOTE: Approximately 90% of the enrolled subjects should have at least one eye with DME at the time of enrollment.

7. The following data will be collected for the study eye(s):

a. Qualifying diagnosis for the study eye from the subject's medical record b. From the subject's medical record, the presence of other ophthalmic conditions including but not limited to: i. Cataract ii. Glaucoma iii. Dry Eye iv. Other macula findings, e.g., epi retinal membrane, macular hole, vitreo-macular traction (VMT)

Following confirmation of subject eligibility, subject will be placed in a room with the NVHO device which has been set up by a technician.

1. The technician will register the subject using the touchscreen of the NVHO device using the subject's CRF number.
2. The subject will perform a self-tutorial. The training flow begins with demonstration clips followed by a practice session. The training flow will be followed by a self-scan that the system uses as a calibration session.
3. Following completion of the training and calibration session, the clinic technician shall set the device for self-scanning flow. The subject will perform four (4) unsupervised self-scans on each study eye with a rest period of ~2 minutes between self-scans.

5. AEs, if applicable, will be collected. 6. Exit subject from the study

• Study Type: Observational
• Enrollment (Actual): 18

Contacts and Locations

• Study Contact: Name: Rina Gottlieb, MA; Phone Number: +794-48886913; Email: rinag@notalvision.com
• Study Contact Backup: Name: Muki Rapp, Phd; Phone Number: +97252-611-8884; Email: rapp@notalvision.com

Study Locations

• Israel
  • Tel Aviv, Israel
    • Assuta HaShalom

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

The study population will include up to thirty (30) patients, with DR in at least one eye at the time of enrollment. All subjects will be enrolled at one (1) site in Israel. The subjects must meet all inclusion / exclusion criteria. Approximately 90% of the enrolled subjects should have at least one eye with DME at the time of enrollment.

Description

Inclusion Criteria:

1. Ability to speak, read and understand Hebrew.
2. Ability to understand and agree to contents of informed consent.
3. Eighteen (18) years of age or older at the time of Informed Consent.
4. Subjects diagnosed with DR (Diabetic Retinopathy) in at least one eye, with or without DME
5. Best corrected Visual Acuity of 20/320 (6/96) or better in eyes participating at the study.

Exclusion Criteria:

1. Subjects with dilated pupils.
2. Subjects with other retinal disease requiring steroidal or anti-VEGF injections.

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
NVHO Total Retinal Fluid (TRF)	volume (nl) measured by NOA (automatic OCT analyzer)	5 minutes
NVHO Intra-Retinal Fluid (IRF)	volume (nl) measured by NOA (automatic OCT analyzer)	5 minutes
NVHO Sub-Retinal Fluid (SRF)	volume (nl) measured by NOA (automatic OCT analyzer)	5 minutes
Zeiss Cirrus OCT Total Retinal Fluid (TRF)	volume (nl) measured by a human reader	10 minutes
Zeiss Cirrus OCT Intra-Retinal Fluid (IRF)	volume (nl) measured by a human reader	10 minutes
Zeiss Cirrus OCT Sub-Retinal Fluid (SRF)	volume (nl) measured by a human reader	10 minutes
Scanning session completion status	complete/incomplete	5 minutes

Collaborators and Investigators

• Sponsor: Notal Vision Inc.

Study record dates

Study Major Dates

• Study Start (Actual): June 29, 2022
• Primary Completion (Actual): November 30, 2022
• Study Completion (Actual): March 30, 2023

Study Registration Dates

• First Submitted: June 9, 2022
• First Submitted That Met QC Criteria: June 9, 2022
• First Posted (Actual): June 14, 2022

Study Record Updates

• Last Update Posted (Actual): June 15, 2023
• Last Update Submitted That Met QC Criteria: June 14, 2023
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Eye Diseases; Endocrine System Diseases; Diabetic Angiopathies; Diabetes Complications; Diabetes Mellitus; Retinal Diseases; Diabetic Retinopathy
• Other Study ID Numbers: C2021.003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No